Caffeine Protects Against Disruptions of the Blood-Brain Barrier in Animal Models of Alzheimer's and Parkinson's Diseases
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Sporadic Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases and as such they represent major public health problems. Finding effective treatments for AD and PD represents an unmet and elusive goal largely because these diseases are chronic and progressive, and have a complicated and ill-understood pathogenesis. Although the underlying mechanisms are not fully understood, caffeine, the most commonly ingested psychoactive drug in the world, has been shown in human and animal studies to be protective against AD and PD. One mechanism implicated in the pathogenesis of AD and PD is blood-brain barrier (BBB) dysfunction and we reported recently that caffeine exerts protective effects against AD and PD at least in part by keeping the BBB intact. The present review focuses on the role of BBB dysfunction in the pathogenesis of AD and PD, caffeine's protective effects against AD and PD, and potential mechanisms whereby caffeine protects against BBB leakage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 2×
“As mentioned earlier, the BBB limits the entry of blood-borne pathogens, substances, drugs, and cells into brain parenchyma and helps regulate and protect the microenvironment of the brain such that once the BBB is disrupted, synaptic and neuronal functions are compromised [5].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE
Reese, T. S., & Karnovsky, M. J. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.34.1.207 · Cited by 2,629 · cited 1×
“system separate from the systemic circulation [1–3] and”
BackgroundFredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 6×
“At higher concentrations, caffeine and its intermediate metabolites such as theophylline, theobromine, and paraxanthine can elevate intracellular cAMP levels by inhibiting cAMP PDE activity [137].”
BackgroundInfluentialOccludin: a novel integral membrane protein localizing at tight junctions.
Furuse, M., Hirase, T., Itoh, M., Nagafuchi, A., Yonemura, S., Tsukita, S., & Tsukita, S. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.6.1777 · Cited by 2,580 · cited 1×
“One of the first transmembrane tight junction proteins described is occludin, a 65 kDa phosphoprotein [7,8].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“compelling evidence supports the amyloid hypothesis of early-onset AD [40,41], which is caused by genetic mutations in the AβPP, presenilin-1 and presenilin-2 genes; all lead to dramatic increases in amyloidogenic processing of AβPP and Aβ production.”
BackgroundRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“LRP-1), and increased Aβ influx (due to increased expression of RAGE) [5,59,62–64].”
BackgroundLindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 2×
“Prospective studies confirmed the above findings by showing that chronic caffeine intake improved memory and cognitive function in normal aged individuals as well as in AD patients [148,151,159–162].”
BackgroundResultCerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 1×
“Subsequent studies confirmed the notion that BBB disruption is a pathological characteristic of AD as evidenced by increased leakage of serum proteins into AD brain parenchyma [48–50], increased cerebrospinal fluid (CSF):serum albumin ratios in AD patients [51– 54], and pathological changes in the microvasculature of…”
BackgroundCoffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090 · cited 1×
“Recent epidemiological and experimental studies indicate that caffeine, when administered chronically, has beneficial effects against a number of acute and chronic neurological disorders including stroke, AD, and PD [144–156].”
BackgroundAsahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004 · cited 1×
“Increasingly, BBB dysfunction has been reported to contribute to PD progression [38,126,127], and it has been found that pesticides disrupt BBB permeability [128], that neuroinflammation and oxidative stress compromises BBB [129–133], that pathological alterations in endothelial cells within the substantial nigra are…”
BackgroundDopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 2×
“Aβ clearance from brain in an isoform-specific manner [61].”
BackgroundBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study
Kivipelto, M., Helkala, E.-L., Hänninen, T., Laakso, M. P., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · Neurology · doi:10.1212/wnl.56.12.1683 · Cited by 717
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 2×
“toxic factors including TNF-α, IL-1 and reactive oxygen species [193,195–198], all of which can disrupt the BBB [24].”
BackgroundProspective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 2×
“Recent epidemiological and experimental studies indicate that caffeine, when administered chronically, has beneficial effects against a number of acute and chronic neurological disorders including stroke, AD, and PD [144–156].”
BackgroundThe role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363
Structural and Functional Regulation of Tight Junctions by RhoA and Rac1 Small GTPases
Jou, T.-S., Schneeberger, E. E., & James Nelson, W. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.142.1.101 · Cited by 354 · cited 1×
“In addition, tight junction proteins are affected by intracellular signaling pathways including levels of intracellular calcium [23–25], vascular endothelial growth factor (VEGF) [26], small G-proteins of the Rho family [21,27–29], and cAMP which stabilizes the BBB [17,30–32].”
BackgroundBlood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Schreibelt, G., Kooij, G., Reijerkerk, A., van Doorn, R., Gringhuis, S. I., van der Pol, S., Weksler, B. B., Romero, I. A., Couraud, P., Piontek, J., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8329com · Cited by 347 · cited 1×
“In addition, tight junction proteins are affected by intracellular signaling pathways including levels of intracellular calcium [23–25], vascular endothelial growth factor (VEGF) [26], small G-proteins of the Rho family [21,27–29], and cAMP which stabilizes the BBB [17,30–32].”
BackgroundThe neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Vorbrodt, A. W., & Dobrogowska, D. H. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00177-2 · Cited by 293 · cited 3×
“ages between the transmembrane proteins and the actin cytoskeleton that occludin, claudins, and ZO proteins stabilize BBB tight junctions [6,16].”
BackgroundUlery, P. G., Beers, J., Mikhailenko, I., Tanzi, R. E., Rebeck, G. W., Hyman, B. T., & Strickland, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7410 · Cited by 271
Adenosine: does it have a neuroprotective role after all?
de Mendonça, A., Sebastião, A. M., & Ribeiro, J. A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00033-3 · Cited by 248 · cited 1×
“subtypes, the main focus continues to be on A2A receptors [169], and preclinical studies suggest strong-”
BackgroundMolecular and cellular permeability control at the blood-brain barrier
Gloor, S. M., Wachtel, M., Bolliger, M. F., Ishihara, H., Landmann, R., & Frei, K. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00102-3 · Cited by 244 · cited 1×
“system separate from the systemic circulation [1–3] and”
BackgroundPhosphorylation of Claudin-5 and Occludin by Rho Kinase in Brain Endothelial Cells
Yamamoto, M., Ramirez, S. H., Sato, S., Kiyota, T., Cerny, R. L., Kaibuchi, K., Persidsky, Y., & Ikezu, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070076 · Cited by 241 · cited 1×
“In addition, tight junction proteins are affected by intracellular signaling pathways including levels of intracellular calcium [23–25], vascular endothelial growth factor (VEGF) [26], small G-proteins of the Rho family [21,27–29], and cAMP which stabilizes the BBB [17,30–32].”
BackgroundSmoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234
van Gelder, B. M., Buijsse, B., Tijhuis, M., Kalmijn, S., Giampaoli, S., Nissinen, A., & Kromhout, D. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602495 · Cited by 228
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218
Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid β Protein Production
Shimizu, H., Tosaki, A., Kaneko, K., Hisano, T., Sakurai, T., & Nukina, N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02185-07 · Cited by 205
Pietrzik, C. U., Busse, T., Merriam, D. E., Weggen, S., & Koo, E. H. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf568 · Cited by 198
Impaired Spine Stability Underlies Plaque-Related Spine Loss in an Alzheimer's Disease Mouse Model
Spires-Jones, T. L., Meyer-Luehmann, M., Osetek, J. D., Jones, P. B., Stern, E. A., Bacskai, B. J., & Hyman, B. T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070055 · Cited by 189
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189 · cited 1×
“Indeed, we reported recently that chronic ingestion of caffeine protected against BBB dysfunction in both a rabbit model of sporadic AD [96] and a mouse model of PD [177].”
BackgroundSelf-citationTNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183 · cited 2×
“Increasingly, BBB dysfunction has been reported to contribute to PD progression [38,126,127], and it has been found that pesticides disrupt BBB permeability [128], that neuroinflammation and oxidative stress compromises BBB [129–133], that pathological alterations in endothelial cells within the substantial nigra are…”
BackgroundCoffee Consumption and Cognitive Function among Older Adults
Johnson-Kozlow, M. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf119 · Cited by 173 · cited 1×
“Prospective studies confirmed the above findings by showing that chronic caffeine intake improved memory and cognitive function in normal aged individuals as well as in AD patients [148,151,159–162].”
ResultKuo, Y.-M., Kokjohn, T. A., Watson, M. D., Woods, A. S., Cotter, R. J., Sue, L. I., Kalback, W. M., Emmerling, M. R., Beach, T. G., & Roher, A. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64947-4 · Cited by 167 · cited 1×
“produced in the periphery [65–67].”
Liu, J., Lu, W., Reigada, D., Nguyen, J., Laties, A. M., & Mitchell, C. H. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0675 · Cited by 141 · cited 1×
“changes in lipids and/or cholesterol metabolism [186– 188], inhibiting endocytosis [189,190],and/or affecting lysosomal pH and trafficking [191,192].”
BackgroundEndothelial dysfunction in lacunar stroke: a systematic review
Knottnerus, I. L. H., Ten Cate, H., Lodder, J., Kessels, F., & van Oostenbrugge, R. J. (2009) · Cerebrovascular Diseases · doi:10.1159/000212672 · Cited by 137
Marzolo, M.-P., & Bu, G. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.10.005 · Cited by 122 · cited 1×
“Furthermore, ApoE4, the major genetic risk factor of sporadic AD, is critical for transportation of cholesterol between cells in brain [81], and is associated with elevated cholesterol levels and an increased risk of developing AD [82–85].”
BackgroundAβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
Dickstein, D. L., Biron, K. E., Ujiie, M., Pfeifer, C. G., Jeffries, A. R., & Jefferies, W. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-3956com · Cited by 111
Chyung, J. H., & Selkoe, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304989200 · Cited by 111 · cited 1×
“The involvement of endosomes/lysosomes was confirmed by findings that Aβ production was decreased in cultured cells that were stably transfected with an AβPP construct where the C-terminal endocytic targeting signal was removed [98, 99], and when cells were transfected with a dominantnegative form of dynamin [100].”
BackgroundThe effects of habitual caffeine use on cognitive change: a longitudinal perspective
VANBOXTEL, M., SCHMITT, J., BOSMA, H., & JOLLES, J. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00171-0 · Cited by 110 · cited 1×
“Prospective studies confirmed the above findings by showing that chronic caffeine intake improved memory and cognitive function in normal aged individuals as well as in AD patients [148,151,159–162].”
ResultGupta, A., Agarwal, R., & Shukla, G. S. (1999) · Human & Experimental Toxicology · doi:10.1177/096032719901800307 · Cited by 85 · cited 1×
“Increasingly, BBB dysfunction has been reported to contribute to PD progression [38,126,127], and it has been found that pesticides disrupt BBB permeability [128], that neuroinflammation and oxidative stress compromises BBB [129–133], that pathological alterations in endothelial cells within the substantial nigra are…”
Background
Cited by
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Cappelletti, S., Daria, P., Sani, G., & Aromatario, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210215655 · Cited by 631
“…this finding deserves further investigation in broader population samples (recreational and professional athletes, untrained individuals) and occasions (during exercise or recovery), caffeine in addition to post-exercise carbohydrates consumption seems to be able to stimulate glycogen resynthesis.”
BackgroundFrom purines to purinergic signalling: molecular functions and human diseases
Huang, Z., Xie, N., Illes, P., Di Virgilio, F., Ulrich, H., Semyanov, A., Verkhratsky, A., Sperlagh, B., Yu, S.-G., Huang, C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00553-z · Cited by 489
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Solfrizzi, V., Custodero, C., Lozupone, M., Imbimbo, B. P., Valiani, V., Agosti, P., Schilardi, A., D’Introno, A., La Montagna, M., Calvani, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170248 · Cited by 352
Duarte, J. M. N., Agostinho, P. M., Carvalho, R. A., & Cunha, R. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0021899 · Cited by 130
Metadata
- Authors
- Chen, X., Ghribi, O., & Geiger, J. D.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-04-14
- Volume
- 20
- Issue
- s1
- Pages
- S127-S141
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1620810572
- Cited by
- 132
- References
- 57
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.